ABCL AbCellera Biologics Inc.
USHealthcareAs of 2026-07-10 16:00
Why ABCL matters now
AbCellera Biologics Inc. (ABCL) is a US stock in Healthcare. The latest InvestLog snapshot shows $6.80 with -6.72% on the session and $2.08B in market capitalization; recent performance reads 1-month +36.54% and YTD +61.70%.
The latest financial table shown here is Q1 2026, with revenue of $8.3M, net income of $-43.2M, and EPS of $-0.14. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -11.2%.
The latest indexable market news headline is "AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $7.50; recent insider activity includes Montalbano John S. filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.79
P/S
21.32
EV/EBITDA
-11.12
DCF Value
$-1.71
FCF Yield
-11.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
79.1%
Operating Margin
-267.6%
Net Margin
-181.7%
ROE
-14.9%
ROA
-11.0%
ROIC
-13.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $8.3M | $-43.2M | $-0.14 |
| Q4 2025 | $44.9M | $-8.9M | $-0.03 |
| FY 2025 | $75.1M | $-146.4M | $-0.49 |
| Q3 2025 | $9.0M | $-57.1M | $-0.19 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$7.50
Target (Median)
$7.50
Target Range
$7.00 - $8.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
CA
Exchange
—
Beta
1.18
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.